Evidence map›Paper›PMID 41874565›Full record

ArticleThe Journal of clinical investigation2026

Four subtypes of disease-causing missense mutations underlie pathogenic protein interactions in neurodegenerative VPS13A disease.

Xing Lin, Yuta Ryoden, Chigure Suzuki, Hiroyuki Ishikawa, Takaharu Sakuragi, Yasuo Uchiyama, Shigekazu Nagata

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xing LinLaboratory of Biochemistry and Immunology, Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
Yuta RyodenLaboratory of Biochemistry and Immunology, Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
Chigure SuzukiDepartment of Cellular and Molecular Pharmacology, and.
Hiroyuki IshikawaLaboratory of Biochemistry and Immunology, Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
Takaharu SakuragiLaboratory of Biochemistry and Immunology, Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.
Yasuo UchiyamaDepartment of Cellular and Neuropathology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Shigekazu NagataLaboratory of Biochemistry and Immunology, Immunology Frontier Research Center, The University of Osaka, Suita, Osaka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VPS13A is an intracellular lipid transfer protein comprising more than 3,000 amino acids. Mutations in human VPS13A cause VPS13A disease, a neurodegenerative disorder that affects movement and cognition. VPS13A forms a complex with the membrane protein XK to mediate ATP-induced phospholipid scrambling in the plasma membrane. Here, we established a mouse cell system expressing full-length mouse VPS13A and examined its interaction with XK. Mutational analysis revealed that VPS13A binds to XK through a C-terminal β-strand that interacts with a β-hairpin in the central region of XK, an interaction essential for scramblase activity. The XK paralog XKR2, which contains a similar β-hairpin structure, also associates with VPS13A and supports phospholipid scrambling. We analyzed 10 mouse VPS13A variants corresponding to human patient mutations and classified them into 4 groups: (a) L67P, I90K, and W2453R, which showed reduced expression; (b) A1091P and M3080R, which were normally expressed but lacked scramblase activity; (c) S1446P, Q2689H, Y2713C, and R3084H, which modestly impaired expression or activity; and (d) I2763R, which altered cell size and disrupted ER independently of XK. These findings define the VPS13A-XK interaction interface, clarify the functional impact of disease-causing mutations, and reveal an unexpected gain-of-function mutation of a VPS13A variant.

Indexed as

Mutation, MissenseNeurodegenerative DiseasesVesicular Transport ProteinsAnimalsHumansMicePhospholipid Transfer ProteinsProtein BindingPhospholipid Transfer ProteinsVesicular Transport ProteinsVPS13A protein, humanVps13a protein, mouseGeneticsNeurodegenerationNeuroscience

Identifiers

PMID41874565
PMCPMC13178662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.